MarketPulse
A

$ASND

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ascendis Pharma Shifts to Direct Nasdaq Listing, Eyes Broader Investor Access

Ascendis Pharma to convert ADS shares to direct Nasdaq listing on 1:1 basis effective April 2026, aiming to expand investor access and index eligibility.
ASNDinstitutional ownershipbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Ascendis Pharma A/S

Ascendis Pharma Wins FDA Clearance for First Weekly Achondroplasia Treatment in Children

Ascendis Pharma wins FDA approval for YUVIWEL, the first once-weekly treatment for pediatric achondroplasia. The therapy offers improved dosing convenience over existing options.
ASNDFDA approvalaccelerated approval